Advanced Multiple Myeloma
May 28, 2020
Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost
The startup focuses on glioblastoma tumors with CAR-T therapy. CAR-T technology that involves genetically modifying a patient’s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted. The scien...
Read More...
May 14, 2020
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost
Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising. The drug limited tumour growth in 43% and shrank tumors in 28% of patients...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
